The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
Labor groups and human rights organizations held their annual Labor Day protest in Manila on Friday,
The Philippines will donate 40 generator sets to Ukraine as humanitarian aid to help restore power
The Department of Education will expand its subsidy program for private school students to cover over
The Land Transportation Office clarified that there is no blanket ban on e-bikes and e-trikes, saying
The Presidential Communications Office commended the National Bureau of Investigation for swiftly arresting former broadcaster Jay